Advaxis Licenses Antigen Delivery Technology to Sellas for Cancer Immunotherapy – Genetic Engineering & Biotechnology News (press release)
Xconomy |
Advaxis Licenses Antigen Delivery Technology to Sellas for Cancer Immunotherapy
Genetic Engineering & Biotechnology News (press release) Advaxis has licensed its proprietary Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358 million for Advaxis, the companies said today. Sellas plans to develop a cancer immunotherapy … Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy Advaxis pens backloaded $358M cancer delivery tech deal |
